Drug
TDF/FTC
TDF/FTC is a pharmaceutical drug with 7 clinical trials. Historical success rate of 66.7%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 4 completed trials
Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(29%)
Phase Distribution
Ph phase_2
1
14%
Ph phase_3
2
29%
Ph phase_4
2
29%
Ph phase_1
1
14%
Phase Distribution
1
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
2(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
4 of 6 finished
Non-Completion Rate
33.3%
2 ended early
Currently Active
0
trials recruiting
Total Trials
7
all time
Status Distribution
Completed(4)
Terminated(2)
Other(1)
Detailed Status
Completed4
Terminated2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Phase 42 (33.3%)
Trials by Status
completed457%
terminated229%
unknown114%
Recent Activity
0 active trials
Showing 5 of 7
terminated
A Pharmacist-run PrEP Program for Women
NCT05755204
completedphase_1
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
NCT03652623
completedphase_4
Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)
NCT03826199
completedphase_3
Expanded PrEP Implementation in Communities in NSW
NCT02870790
completedphase_3
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
NCT01227824
Clinical Trials (7)
Showing 7 of 7 trials
NCT05755204
A Pharmacist-run PrEP Program for Women
NCT03652623Phase 1
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
NCT03826199Phase 4
Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)
NCT02870790Phase 3
Expanded PrEP Implementation in Communities in NSW
NCT01227824Phase 3
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
NCT02415595Phase 2
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
NCT02593409Phase 4
HIV PrEP Priming of Immune Effectors
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7